SEOUL-SEMICONDUCTOR
29.10.2021 09:20:08 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that following Seoul National University in Korea and Basel University in Europe, a research team found that exposure to short-wavelength enriched light with daylight-like spectrum improves key components of learning such as working memory, cognitive processing speed, and testing accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211029005138/en/
The clinical trial began in 2019, conducted by the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, and included college-aged adults. The results from the study clearly showed the effectiveness of improving procedural learning.
Shadab Rahman, PhD MPH, a researcher in the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital and Assistant Professor of Medicine at Harvard Medical School, led the study along with Leilah Grant, PhD, Melissa St. Hilaire, PhD, Steven Lockley, PhD, and other researchers at the Brigham. Dr. Rahman said, “Even if the color temperature and brightness are the same, light with different spectra may affect non-visual responses to light exposure, including those of circadian rhythms and cognition, differently. In this experiment, we found improvement in working memory, cognitive processing speed, procedural learning, and testing accuracy with young adults under daylight-like light spectrum lighting compared to conventional-LED spectrum lighting. This is an important result that can inform lighting choices for indoor use to enhance students’ learning and memory function.”
The daylight-like spectrum lighting used in the study was provided by Seoul Semiconductor Co., Ltd., makers of SunLike. SunLike is an optical semiconductor technology that reproduces the natural sunlight spectrum curve, that is, the intensity of light for each wavelength of red, orange, yellow, green, blue, and purple. This new concept of LED light source embodies almost the same characteristics of natural light and is optimized for human 24-hour circadian rhythm accordingly.
There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: ‘Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,’ published in the Journal of Lighting and Research Technology on March 24, 2019. In addition, in an experiment at Seoul National University College of Medicine in July 2018, it was demonstrated that vitality and alertness were increased when SunLike LED lighting was used.
“As the saying goes, ‘Mother Nature is great’, the human body has a 24-hour circadian clock that has evolved to set its time by tracking the daily cycle of sunlight. SunLike is a technology that reproduces all wavelengths of visible light as closely as possible to sunlight. We've been working on R&D over the past 30 years to optimize this technology to provide plants, animals and humans access to light that is closest to sunlight to promote healthy circadian rhythms and sleep, which can also help children and students to study effectively and maintain good health”, said Chung-hoon Lee, CEO of Seoul Semiconductor.
Seoul Semiconductor and Toshiba Materials were jointly involved in the development and release of SunLike in 2017, which has needed investment to further expand stable production and sales. As a result of continuous consultations between the two companies over the past two years to improve the speed of decision and operational efficiency for the SunLike business, Seoul Semiconductor has acquired all technologies, patents, trademarks, etc. related to SunLike, the light most similar to sunlight. Key workers from Toshiba Materials also joined Seoul Semiconductor, and they began efforts to expand sales from September.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005138/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom